ArticleNeurotoxicity research2009
Fifteen-year experience in treating blepharospasm with Botox or Dysport: same toxin, two drugs.
Article in Neurotoxicity research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 3 syntheses or guidelines pooled it, 73 citations in OpenAlex.
- Bibliometric analysis of studies on the treatment of hemifacial spasm.Frontiers in neurology · 2022Pooled it
- Guideline
- Efficacy and safety of long-term botulinum toxin treatment in craniocervical dystonia: a systematic review.Neurotoxicity research · 2012Pooled it
- Article
- Article
- Clinical Features and Evolution of Blepharospasm: A Multicenter International Cohort and Systematic Literature Review.Dystonia (Lausanne, Switzerland) · 2022Article
- Nonlinear Changes in Botulinum Toxin Treatment of Task-Specific Dystonia during Long-Term Treatment.Toxins · 2021Article
- The Use of Botulinum Toxin for Treatment of the Dystonias.Handbook of experimental pharmacology · 2021Article
- FDA Approvals and Consensus Guidelines for Botulinum Toxins in the Treatment of Dystonia.Toxins · 2020Review
- Treatment of blepharospasm and Meige's syndrome with abo- and onabotulinumtoxinA: long-term safety and efficacy in daily clinical practice.Journal of neurology · 2020Observational
- Review
- Botulinum neurotoxin formulations: overcoming the confusion.Clinical, cosmetic and investigational dermatology · 2018Review
- Long-Term Abobotulinumtoxin A Treatment of Cervical Dystonia.Neurotoxicity research · 2017Article
- Use of Botulinum Neurotoxin in Ophthalmology.Turkish journal of ophthalmology · 2016Review
- Considerations on patient-related outcomes with the use of botulinum toxins: is switching products safe?Therapeutics and clinical risk management · 2016Review
- Botulinum toxin in the management of blepharospasm: current evidence and recent developments.Therapeutic advances in neurological disorders · 2015Review
- Blepharospasm: long-term treatment with either Botox®, Xeomin® or Dysport®.Journal of neural transmission (Vienna, Austria : 1996) · 2015Article
- None detectable retrograde transport of Chinese botulinum toxin type A in mice by single intramuscular injection.International journal of clinical and experimental medicine · 2015Article
- Systematic Literature Review of AbobotulinumtoxinA in Clinical Trials for Blepharospasm and Hemifacial Spasm.Tremor and other hyperkinetic movements (New York, N.Y.) · 2015Review
- Influence of injection of Chinese botulinum toxin type A on the histomorphology and myosin heavy chain composition of rat gastrocnemius muscles.Journal of Zhejiang University. Science. B · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo compare the clinical characteristics and the long-term outcome of a large series of patients with blepharospasm (BS) treated with the two most used brands of BoNT-A over the last 15 years.
methodsWe have reviewed the clinical charts of 128 patients with BS who received botulinum neurotoxin (BoNT) in 1341 treatments (Botox in 1009, Dysport in 332) over the last 15 years.
resultsMean dose per session was 34U +/- 15 for Botox and 152U +/- 54 for Dysport. Mean latency of clinical effect was 4.5 +/- 4.6 days for Botox and 5.0 +/- 5.7 days for Dysport (P > 0.05). Mean duration of clinical improvement was higher for Dysport than Botox: 80.1 +/- 36.3 and 66.2 +/- 39.8 days, respectively (P < 0.01). In a six-point scale (0: no efficacy, 6: remission of BS), the mean efficacy of both treatments was 3.60 +/- 1.3; 3.51 +/- 1.4 (Botox) and 3.85 +/- 1.2 (Dysport), P < 0.01. The doses of Botox (beta = 0.40) and Dysport (beta = 0.16) were significantly increased over time. Side effects occurred in 325 out of 1341 treatments (24.2%): 21.8% of the patients who had received Botox, and in 31.6% of those who had received Dysport (P < 0.01).
conclusionsBoth brands are effective and safe in treating blepharospasm; efficacy is long lasting. The differences in outcome and side effects suggest that, albeit the active drug is the same, Botox and Dysport should be considered as two different drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.